Drugs / 68GaNOTA-Anti-MMR-VHH2
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04168528 | Nov 2019 → Dec 2024 | breast cancer, cutaneous melanoma | University Hospital Brussels | Terminated | No outcome recorded Stop: Enrollment |
| Phase 22 trials | ||||||
| Phase 2 | NCT05933239 | Mar 2023 → Apr 2027 expected | non-small cell lung carcinoma | University Hospital Brussels | Recruiting | No outcome recorded |
| Phase 2 | NCT04758650 | Jan 2021 → Jan 2025 | Hodgkins lymphoma, atherosclerosis, cancer, cardiac sarcoidosis +4 | University Hospital Brussels | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68GaNOTA-Anti-MMR-VHH2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04758650 ↗ |
| Modality | Diagnostic / imaging agent | “a New Radiopharmaceutical for in Vivo Imaging of Tumour-Associated Macrophages” NCT04168528 ↗ |
| Route | Other | “Injection of the radiopharmaceutical and PET/CT imaging” NCT04168528 ↗ |